{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:32:03Z","timestamp":1745483523626,"version":"3.38.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.2169\/internalmedicine.3907-24","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T22:10:45Z","timestamp":1721859045000},"page":"673-678","source":"Crossref","is-referenced-by-count":2,"title":["Fournier's Gangrene in the Course of Treatment of Advanced Hepatocellular Carcinoma with Molecular-targeted Therapy"],"prefix":"10.2169","volume":"64","author":[{"given":"Yusuke","family":"Komeda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsaku","family":"Nagamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana","family":"Sueki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoma","family":"Kikukawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Uejima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Moriya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nara Prefecture General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55: 113-122, 2020.","DOI":"10.1007\/s00535-019-01642-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Smith SW. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database. A disproportionally analysis. Drug Saf 35: 507-518, 2012.","DOI":"10.2165\/11597600-000000000-00000"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kozloff M, Yood MU, Berlin J, et al. Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14: 862-870, 2009.","DOI":"10.1634\/theoncologist.2009-0071"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19: 577-582, 2008.","DOI":"10.1093\/annonc\/mdm508"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gamboa EO, Rehmus EH, Haller N. Fournier&apos;s gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Clin Colorectal Cancer 9: 55-58, 2010.","DOI":"10.3816\/CCC.2010.n.008"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ugai T, Norizuki M, Mikawa T, Ohji G, Yaegashi M. Necrotizing fasciitis caused by <i>Haemophilus influenzae<\/i> type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report. BMC Infect Dis 14: 198, 2014.","DOI":"10.1186\/1471-2334-14-198"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Haider A, Gurjar H, Ghazanfar H, Chilimuri S. Necrotizing fasciitis in a patient with metastatic clear cell ovarian carcinoma treated with bevacizumab. Am J Case Rep 23: e935584, 2022.","DOI":"10.12659\/AJCR.935584"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sendur MA, Aksoy S, \u00d6zdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol 46: 125-126, 2014.","DOI":"10.4103\/0253-7613.125195"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yanar H, Taviloglu K, Ertekin C, et al. Fournier&apos;s gangrene; risk factors and strategies for management. World J Surg 30: 1750-1754, 2006.","DOI":"10.1007\/s00268-005-0777-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Robert SR, Masood AK. Mortality associated with Fournier&apos;s gangrene remains unchanged over 25 years. BJU Int 125: 610-616, 2020.","DOI":"10.1111\/bju.14998"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sorensen MD, Krieger JN. Fournier&apos;s gangrene: epidemiology and outcomes in the general US population. Urol Int 97: 249-259, 2016.","DOI":"10.1159\/000445695"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hakkarainen TW, Kopari NM, Pham TN, Enans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg 51: 344-362, 2014.","DOI":"10.1067\/j.cpsurg.2014.06.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hua C, Urbina T, Bosc R, et al. Necrotising soft-tissue infections. Lancet Infect Dis 23: e81-e94, 2023.","DOI":"10.1016\/S1473-3099(22)00583-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Barone M, Grani G, Ramundo V, Garritano T, Durante C, Falcone R. Fournier&apos;s gangrene during lenvatinib treatment: a case report. Mol Clin Oncol 12: 588-591, 2020.","DOI":"10.3892\/mco.2020.2031"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Repana D, Ross P. Targeting FGF19\/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma. Diseases 3: 294-305, 2015.","DOI":"10.3390\/diseases3040294"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Katoh M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis. Int J Mol Med 38: 3-15, 2016.","DOI":"10.3892\/ijmm.2016.2620"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 20: 638747, 2014.","DOI":"10.1155\/2014\/638747"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3907-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:35:07Z","timestamp":1740800107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3907-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3907-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"article-number":"3907-24"}}